Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Oxid Med Cell Longev ; 2020: 8819719, 2020.
Article in English | MEDLINE | ID: mdl-33204398

ABSTRACT

Oxidative (OS), reductive (RS), and nitrosative (NSS) stresses produce carbonylation, glycation, glutathionylation, sulfhydration, nitration, and nitrosylation reactions. OS, RS, and NSS are interrelated since RS results from an overactivation of antioxidant systems and NSS is the result of the overactivation of the oxidation of nitric oxide (NO). Here, we discuss the general characteristics of the three types of stress and the way by which the reactions they induce (a) damage the DNA structure causing strand breaks or inducing the formation of 8-oxo-d guanosine; (b) modify histones; (c) modify the activities of the enzymes that determine the establishment of epigenetic cues such as DNA methyl transferases, histone methyl transferases, acetyltransferases, and deacetylases; (d) alter DNA reparation enzymes by posttranslational mechanisms; and (e) regulate the activities of intracellular enzymes participating in metabolic reactions and in signaling pathways through posttranslational modifications. Furthermore, the three types of stress may establish new epigenetic marks through these reactions. The development of cardiometabolic disorders in adult life may be programed since early stages of development by epigenetic cues which may be established or modified by OS, RS, and NSS. Therefore, the three types of stress participate importantly in mediating the impact of the early life environment on later health and heritability. Here, we discuss their impact on cardiometabolic diseases. The epigenetic modifications induced by these stresses depend on union and release of chemical residues on a DNA sequence and/or on amino acid residues in proteins, and therefore, they are reversible and potentially treatable.


Subject(s)
Cardiovascular Diseases/enzymology , Cardiovascular Diseases/genetics , Metabolic Diseases/enzymology , Metabolic Diseases/genetics , Nitrosative Stress/physiology , Oxidative Stress/physiology , Protein Processing, Post-Translational , Animals , Cardiovascular Diseases/metabolism , Cardiovascular Diseases/pathology , Epigenesis, Genetic , Humans , Metabolic Diseases/metabolism , Metabolic Diseases/pathology , Signal Transduction
2.
Peptides ; 57: 101-8, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24819472

ABSTRACT

Renin-Angiotensin System (RAS) plays an important role in the development of Metabolic Syndrome (MS) and in aging. Angiotensin 1-7 (Ang 1-7) has opposite effects to Ang II. All of the components of RAS are expressed locally in adipose tissue and there is over-activation of adipose RAS in obesity and hypertension. We determined serum and abdominal adipose tissue Ang II and Ang 1-7 in control and MS rats during aging and the expression of AT1, AT2 and Mas in white adipose tissue. MS was induced by sucrose ingestion during 6, 12 and 18 months. During aging, an increase in body weight, abdominal fat and dyslipidemia were found but increases in aging MS rats were higher. Control and MS concentrations of serum Ang II from 6-month old rats were similar. Aging did not modify Ang II seric concentration in control rats but decreased it in MS rats. Ang II levels increased in WAT from both groups of rats. Serum and adipose tissue Ang 1-7 increased during aging in MS rats. Western blot analysis revealed that AT1 expression increased in the control group during aging while AT2 and Mas remained unchanged. In MS rats, AT1 and AT2 expression decreased significantly in aged rats. The high concentration of Ang 1-7 and adiponectin in old MS rats might be associated to an increased expression of PPAR-γ. PPAR-γ was increased in adipose tissue from MS rats. It decreased with aging in control rats and showed no changes during aging in MS rats. Ang 1-7/Mas axis was the predominant pathway in WAT from old MS animals and could represent a potential target for therapeutical strategies in the treatment of MS during aging.


Subject(s)
Angiotensin II/metabolism , Angiotensin I/metabolism , Metabolic Syndrome/genetics , Peptide Fragments/metabolism , Proto-Oncogene Proteins/biosynthesis , Receptor, Angiotensin, Type 2/biosynthesis , Receptors, Angiotensin/biosynthesis , Receptors, G-Protein-Coupled/biosynthesis , Adipose Tissue, White/metabolism , Aging/genetics , Aging/metabolism , Aging/pathology , Animals , Gene Expression Regulation , Humans , Hypertension/genetics , Hypertension/pathology , Metabolic Syndrome/metabolism , Metabolic Syndrome/pathology , Proto-Oncogene Mas , Rats , Renin-Angiotensin System/genetics
SELECTION OF CITATIONS
SEARCH DETAIL